Atea Pharmaceuticals, Inc. (AVIR) SEC Filings — 2025
16 SEC filings for Atea Pharmaceuticals, Inc. (AVIR) in 2025.
Filings
- Atea's Q3 Loss Widens Amid Increased R&D for HCV Program — 10-Q · Nov 12, 2025
- Atea Pharmaceuticals Files 8-K on Financials — 8-K · Aug 7, 2025
- Atea Narrows Q2 Loss to $45.2M Amid R&D Cost Cuts — 10-Q · Aug 7, 2025
- Atea Pharmaceuticals Files 8-K for Shareholder Vote Matters — 8-K · Jun 20, 2025
- Atea Pharmaceuticals Files 8-K on Financials — 8-K · May 12, 2025
- Atea Pharma Files Q1 2025 10-Q, Notes Merck Deal — 10-Q · May 12, 2025
- Atea Pharmaceuticals Files 2024 DEF 14A — DEF 14A · Apr 29, 2025
- Atea Pharmaceuticals Files 8-K with Key Corporate Updates — 8-K · Apr 17, 2025
- Atea Pharmaceuticals Files Proxy Statement — DEFA14A · Apr 3, 2025
- Atea Pharma Proxy Solicitation Filing — DEFA14A · Apr 1, 2025
- Atea Pharmaceuticals Files Proxy Statement — DEFA14A · Mar 26, 2025
- Atea Pharmaceuticals Files 8-K for Financials — 8-K · Mar 24, 2025
- Atea Pharmaceuticals Files 8-K on Financials — 8-K · Mar 6, 2025
- Atea Pharmaceuticals Files 2024 10-K — 10-K · Mar 6, 2025
- Atea Pharmaceuticals Announces Board and Executive Changes — 8-K · Feb 24, 2025
- Atea Pharmaceuticals Files 8-K on Financials — 8-K · Jan 14, 2025